PT - JOURNAL ARTICLE AU - Alex Adams AU - Vipin Gupta AU - Waled Mohsen AU - Thomas P Chapman AU - Deloshaan Subhaharan AU - Pradeep Kakkadasam Ramaswamy AU - Sudheer Kumar Vuyyuru AU - Saurabh Kedia AU - Colleen GC McGregor AU - Tim Ambrose AU - Bruce D George AU - Rebecca Palmer AU - Oliver Brain AU - Alissa Walsh AU - Vineet Ahuja AU - Simon Travis AU - Jack Satsangi TI - Optimising Early Management of Acute Severe Ulcerative Colitis in the Biologics Era: Admission Model for Intensification of Therapy in Acute Severe Colitis (ADMIT–ASC) AID - 10.1101/2021.07.14.21260477 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.14.21260477 4099 - http://medrxiv.org/content/early/2021/07/15/2021.07.14.21260477.short 4100 - http://medrxiv.org/content/early/2021/07/15/2021.07.14.21260477.full AB - Background & aims We aimed to determine whether changes in ulcerative colitis management have translated to improved outcomes, in order to develop a simple model to predict steroid non-response on admission.Methods Outcomes of 131 adult ASC admissions (117 patients) in Oxford, UK between 2015-19 were compared with prospectively collected data from 1992-3. All patients received standard treatment with intravenous corticosteroids and endoscopic disease activity scoring (UCEIS). Steroid non-response was defined as receiving rescue medical therapy or surgery. A predictive model created in the Oxford cohort was validated in Australia and India (110 hospitalised patients Gold Coast University Hospital 2015-20; 62 hospitalised patients AIIMS, New Delhi 2018-20).Results In the 2015-19 Oxford cohort, 71 (54%) patients received medical rescue therapy (27% ciclosporin, 27% anti-TNF), compared to 27% ciclosporin in 1992-3, p=0.0015. Only 15% required colectomy during admission vs 29% in 1992-3 (p=0.033). Admission CRP, albumin, and UCEIS scores predicted steroid non-response (FDR p=0.00066, 0.0066 and 0.015). A four-point model was developed involving CRP ≥100mg/L (1 point), albumin ≤25g/L (1 point), UCEIS ≥4 (1 point) or ≥7 (2 points). Scoring 0 or 4 was 100% predictive of steroid response and non-response, respectively, in all three cohorts. Patients scoring 3-4 had 83% risk of steroid non-response in Oxford and 84% (0.70-0.98) in the validation cohorts – OR 11.9 (10.8-13).Conclusion Colectomy rates for ASC have halved in 25 years, while use of rescue medical therapy has doubled. Patients who are highly unlikely to respond to parenteral steroid treatment alone may be readily identified on admission, to be prioritised for early intensification of therapy.Background and context Acute severe colitis (ASC) requires hospitalisation and, frequently, colectomy. The accepted management of ASC is three-five days of intravenous steroids followed by protocolised response assessment.New findings Medical rescue therapy has doubled and the colectomy rate halved in 25 years. A predictive index identifying steroid non-response was derived and validated in three independent centres in three countries.Limitations A need remains to demonstrate that earlier rescue medical therapy for patients predicted to be steroid non-responders will further improve outcomes.Impact The outcome of ASC has substantially improved in the past 25 years, with the potential for further improvement by identifying patients on admission for early escalation of therapy.Competing Interest StatementVG, WM, AA, TC, DS, PR, SKV, SK, CM, TA, BG, RP, OB, and VA declare no competing interests. AW reports personal fees outside the submitted work from Ferring Pharmaceuticals, Janssen, and Takeda. ST reports outside the submitted work receipt of grants/research support from AbbVie, Buhlmann, Celgene, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, Vifor, and Norman Collisson Foundation; consulting fees from AbbVie, Allergan, Amgen, Arena, Asahi, Astellas, Biocare, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Buhlmann, Celgene, Chemocentryx, Cosmo, Enterome, Ferring, Giuliani SpA, GSK, Genentech, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Merck, MSD, Neovacs, Novartis, NovoNordisk, NPS Pharmaceuticals, Pfizer, Proximagen, Receptos, Roche, Sensyne, Shire, Sigmoid Pharma, SynDermix, Takeda, Theravance, Tillotts, Topivert, UCB, VHsquared, Vifor, and Zeria; speaker fees from AbbVie, Amgen, Biogen, Ferring, Janssen, Lilly, Pfizer, Shire, and Takeda; no stocks or share options. JS has received lecture fees from Takeda and from the Falk Foundation.Funding StatementThis work is funded by the Oxford NIHR Biomedical Research Centre - Gastroenterology and Mucosal Immunology Theme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval in Oxford was granted through the National Health Service Health Research Authority REC 16/YH/0247 and 09/H1204/30, in Gold Coast by Health Service Human Research Ethics Committee (Ref: LNR/2020/QGC/67173), and in Delhi by AIIMS ethics committee (Ref: IEC-261/04.05.2018)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact the corresponding authors for access to anonymised data.